Clinical Trial Update: STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of ganetespib (STA-9090) in unresectable Stage III or Stage IV melanoma. The study was terminated and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• STA-9090 (ganetespib) (ganetespib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-04-12